Cargando…

Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment

PURPOSE: Esaxerenone is a novel, oral, nonsteroidal treatment for hypertension. Physiologically based pharmacokinetic (PBPK) modelling was performed to predict the drug–drug interaction (DDI) effect of cytochrome P450 (CYP)3A modulators on esaxerenone pharmacokinetics in healthy subjects and subject...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watanabe, Akiko, Ishizuka, Tomoko, Yamada, Makiko, Igawa, Yoshiyuki, Shimizu, Takako, Ishizuka, Hitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Pharmacokinetics and Disposition
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724184/ https://www.ncbi.nlm.nih.gov/pubmed/34415382 http://dx.doi.org/10.1007/s00228-021-03194-x

Ejemplares similares

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients
por: Senek, Marina, et al.
Publicado: (2018)

Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function
por: Teng, Renli, et al.
Publicado: (2018)

Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis
por: Dymond, Angela W., et al.
Publicado: (2017)

Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment
por: Wu, Wanhong, et al.
Publicado: (2021)

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
por: Shi, Hui-Yan, et al.
Publicado: (2010)

Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers
por: Orrell, Catherine, et al.
Publicado: (2008)

Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers
por: Tanaka, Jun, et al.
Publicado: (2012)

Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males
por: Toyama, Kaoru, et al.
Publicado: (2021)

The effect of dipyridamole on the pharmacokinetics of metformin: a randomized crossover study in healthy volunteers
por: El Messaoudi, S., et al.
Publicado: (2016)

Predictive performance of parent-metabolite population pharmacokinetic models of (S)-ketamine in healthy volunteers
por: Otto, M. E., et al.
Publicado: (2021)

Plasma pharmacokinetics and synovial concentrations of S-flurbiprofen plaster in humans
por: Yataba, Ikuko, et al.
Publicado: (2015)

Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials
por: Dymond, Angela W., et al.
Publicado: (2016)

Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers
por: Navaratnam, Visweswaran, et al.
Publicado: (2009)

Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults
por: Webb, Nicholas J. A., et al.
Publicado: (2016)

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
por: Small, David S., et al.
Publicado: (2016)

Population pharmacokinetics of cefotaxime in intensive care patients
por: Swartling, Maria, et al.
Publicado: (2021)

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
por: Fasanmade, Adedigbo A., et al.
Publicado: (2009)

Population pharmacokinetics of haloperidol in terminally ill adult patients
por: Franken, L. G., et al.
Publicado: (2017)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
por: Kurata, Akifumi, et al.
Publicado: (2019)

A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib
por: Atiq, Ferdows, et al.
Publicado: (2016)

Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients
por: Abdulla, Alan, et al.
Publicado: (2020)

Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients
por: Francke, M. I., et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler
por: Breuer, C., et al.
Publicado: (2013)

A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents
por: Ogungbenro, Kayode, et al.
Publicado: (2019)

Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies
por: Wasmann, Roeland E., et al.
Publicado: (2020)

Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years
por: Schoemaker, Rik, et al.
Publicado: (2017)

Single dose epidural hydromorphone in labour pain: maternal pharmacokinetics and neonatal exposure
por: Puhto, Terhi, et al.
Publicado: (2020)

Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model
por: Stillemans, Gabriel, et al.
Publicado: (2020)

The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers
por: Tylleskar, Ida, et al.
Publicado: (2021)

Effects of itraconazole and rifampicin on the single‐dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

An open-label, positron emission tomography study of the striatal D(2)/D(3) receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants
por: Wong, Dean F., et al.
Publicado: (2020)

Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens
por: Oesterreicher, Zoe, et al.
Publicado: (2017)

Levodopa/carbidopa microtablets in Parkinson’s disease: a study of pharmacokinetics and blinded motor assessment
por: Senek, Marina, et al.
Publicado: (2017)

Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients
por: Yao, Xueting, et al.
Publicado: (2020)

In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates
por: Preijers, Tim, et al.
Publicado: (2021)

Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients
por: Andreassen, Trine Naalsund, et al.
Publicado: (2010)

Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients
por: Oosten, Astrid W., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ucin0eu6ofiagndhn8peorrjog